Retigabine -(BNF)- Anti-epileptics
Drug Name:Retigabine -(BNF)- Anti-epileptics
List Of Brands:
Indication Type Description:
Indication
Adverse Reaction
Contra-Indications
Dosages/ Overdosage Etc
Pregnancy and lactation
Indication:
Ref- BNF (British National Formulary- March 2015)
Indications-
Adjunctive treatment of drug-resitent focal seizures with or
without secondary generalisation
To be prescibed only when other appropiate drug combinations
have proved inadequate or have not been tolerated
Adverse Reaction:
Side effects-
increased appetite, weigh gain, nausea,
constipation, dyspepsia, dry mouth, perpheral edema.
malaise, drowsiness, dizziness, vertigo,
amnesia, parasethesia, tremor, impaired speech and attention,
myoclonus, confusion, psychosis, anxiety, dysuria, hematuria,
diplopia, blurred vision, discoloration of ocular tissue,
visual impairment, discolration of nails, lips and skin
less commonly dyspegia, hypkinesia, urinary retension,
nephrolithiasis, rash, sweating and sucidal ideation
Contra-Indications:
Cautions-
avoid abrupt withdrawal, risk of urinary retension ,
known QT prolongation
monitorfor discolration of occular tissue and visual impairment
monitor for blue-grey discolorstion of nails, lips and skin
continue treatment only if potential benefits outweighs risks
QT-interval prologation-
patients with known QT prolongation or with risk factors to
QT interval ptolongation- should be carefully monitores
Ophthalmological monitoring-
should be performes at initiation of treatment and at least afer 6 months
of prologed treatment
Switiching between formulation-
care should be taken when switching between formulation.
need for continued supplu of a partcular manufacturer should be
based on clinical judgement and consultation with the patient
and their caregiver
Hepatic impairment-
reduce dose by 50% in moderate to severe impairment,
increase by 50mg every week according to response up to
a max.f 600mg daily (450mg in elderely)
Renal impairment-
reduce dose by 50% if eGFR less than 50mL/1.73m2
increase by 50mg every week according to response
up to a max of 600mg daily (450mg in elderly)
Dosages/ Overdosage Etc:
Ref- BNF (British National Formulary- March 2015)
BRAND - TROBAIT
MANUFACTURER - GSK
GLAXOSMITHKLINE
TEL 0800 221 441
customer.relations@gsk.com
Indications-
Adjunctive treatment of drug-resitent focal seizures with or
without secondary generalisation
To be prescibed only when other appropiate drug combinations
have proved inadequate or have not been tolerated
Dose-
Adult- over 18 years- initially upto 300mg daily in 3 divided doses
increased accoding to response by upto 150mg evey week
upto a maintenance dose of 0.6 - 1.2g daily
Elderly- over 65 years- initially 150mg daily in 3 divided doses
increase according to response upto 150mg every week
max dose 900mg daily
Pregnancy and lactation:
Pregnancy-
women of child bearing age should discuss with a specialist in the respect
of both epilepsy and treatment
should be avoided during pregnancy
Breast feeding-
women taking antiepileptic monotherapy should generally be encoraged
to breast-feed, if a woman is on combination therapy or if other risk factors,
specialist advice should be sought
All infants should be monitored for sedation
